Vanda Pharmaceuticals announced that it has received a complete response letter from the FDA for its potential treatment for jet lag.
The drug, Hetlioz, has already been approved to treat non-24-hour sleep-wake disorder, which disrupts the circadian rhythms that regulate normal sleeping patterns. Vanda submitted its application for Hetlioz as a treatment for jet lag disorder based on trials showing that people slept for nearly three hours longer for three nights following a transatlantic flight when taking the drug than they did without it.
But the FDA said there was not enough information to prove there is a clinical benefit to the treatment.
Vanda reported in a press release that it is “perplexed” by the agency’s conclusion. But the company said it will continue working with the FDA to gain marketing approval for Hetlioz as a jet lag treatment, which the company said is currently an unmet medical need.
Read the press release.
Don't miss your Daily Dose. Get news like this delivered right to your inbox.